Darolutamide in nonmetastatic, castration-resistant prostate cancer

This paper reports a randomized, double-blind, placebo-controlled, phase 3 trial of darolutamide, a novel oral androgen-receptor antagonist, in 1509 men with non-metastatic, castration-resistant prostate cancer. Median metastasis-free survival was significantly longer with darolutamide (40.4 months) than placebo (18.4 months; hazard ratio for metastasis or death: 0.41; 95% CI, 0.34 to 0.50; P<0.001).